Psoriasis treatment and biologic switching: The association with clinical characteristics and laboratory biomarkers over a 13‐year retrospective study

The advent of biologics has greatly improved patient outcomes, yet some patients are compelled to switch therapies. Predicting these therapeutic failures is important; however, the factors associated with switching biologics have not been fully explored. This study examined patterns and determinants...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2024-12, Vol.51 (12), p.1572-1578
Main Authors: Koyama, Asumi, Li, Lixin, Yamamoto, Toyoki, Taira, Haruka, Sugimoto, Eiki, Ito, Yukiko, Mizuno, Yuka, Awaji, Kentaro, Tateishi, Shoko, Kanda, Hiroko, Sato, Shinichi, Shibata, Sayaka
Format: Article
Language:English
Subjects:
Adult
Aged
Biological Products - therapeutic use
biologics therapy
Biomarkers
Biomarkers - blood
Biopharmaceuticals
Dermatologic Agents - therapeutic use
Drug Substitution
drug survival
Female
Humans
Leukocytes (neutrophilic)
Lymphocytes
Male
Middle Aged
Neutrophils
Original
Patients
Psoriasis
Psoriasis - blood
Psoriasis - diagnosis
Psoriasis - drug therapy
Retrospective Studies
Severity of Illness Index
Treatment Outcome
treatment patterns
treatment switching
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The advent of biologics has greatly improved patient outcomes, yet some patients are compelled to switch therapies. Predicting these therapeutic failures is important; however, the factors associated with switching biologics have not been fully explored. This study examined patterns and determinants of biologics switching in psoriasis treatment retrospectively over 13 years. We focused on the association between clinical characteristics, basal laboratory data, and frequency of biologics switching. The findings revealed that elevated Psoriasis Area Severity Index scores and the presence of arthritis were observed in patients who experienced two or more treatment switches compared with those without treatment switches. Moreover, neutrophil to lymphocyte ratio was associated with higher biologics switching rates, indicating that systemic inflammation significantly impacts treatment adherence. A treatment approach, taking into account both the clinical presentation and inflammatory biomarkers, may be important for optimizing patient management in psoriasis.
ISSN:0385-2407
1346-8138
1346-8138
DOI:10.1111/1346-8138.17465